Aelix Therapeutics: Funding, Investors & Team (Sep 2026)
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.
Aelix Therapeutics has raised $2.2M across 1 funding round on record, the most recent an undisclosed round of $2.2M announced in Sep 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aelix Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2021.
Aelix Therapeutics Funding Rounds
Aelix Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Aelix Therapeutics Funding Compared to Other Biotechnology Startups
Aelix Therapeutics' latest round of $2.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aelix Therapeutics in Biotechnology and Barcelona
Companies Similar to Aelix Therapeutics
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun…
Aelix Therapeutics Funding FAQs
What does Aelix Therapeutics do?
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.
How much funding has Aelix Therapeutics raised?
Aelix Therapeutics has raised $2.2M across 1 round on record. The most recent is an undisclosed round of $2.2M announced in Sep 2021.
When did Aelix Therapeutics last raise funding?
Aelix Therapeutics' most recent funding round on record is an undisclosed round of $2.2M, announced in Sep 2021.
Who is the CEO of Aelix Therapeutics?
Melanie Rolli is listed as CEO at Aelix Therapeutics.
Where is Aelix Therapeutics headquartered?
Aelix Therapeutics is based in Barcelona, Catalonia, Spain.
How many employees does Aelix Therapeutics have?
Aelix Therapeutics is in the 11-50 employee band.
How does Aelix Therapeutics' funding compare to other Biotechnology startups?
Aelix Therapeutics' latest round of $2.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Aelix Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aelix Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.